Reasonable osteoporosis prevention: hormone replacement therapy, SERM, or bisphosphonate?

被引：1
作者：
Marcelli, C [1 ]
机构：
[1] CHU Caen, Serv Rhumatol, F-14033 Caen, France
来源：
JOINT BONE SPINE | 2000年 / 67卷 / 06期
关键词：
bisphosphonate; osteoporosis; postmenopausal hormone replacement therapy;
D O I：
10.1016/S1297-319X(00)00209-8
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：579 / 581
页数：3
相关论文
共 14 条
  • [11] Alendronate prevents postmenopausal bone loss in women without osteoporosis - A double-blind, randomized, controlled trial
    McClung, M
    Clemmesen, B
    Daifotis, A
    Gilchrist, NL
    Eisman, J
    Weinstein, RS
    El-Hajj Fuleihan, G
    Reda, C
    Yates, AJ
    Ravn, P
    [J]. ANNALS OF INTERNAL MEDICINE, 1998, 128 (04) : 253 - +
  • [12] Risedronate increases bone mass in an early postmenopausal population: Two years of treatment plus one year of follow-up
    Mortensen, L
    Charles, P
    Bekker, PJ
    Digennaro, J
    Johnston, CC
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (02) : 396 - 402
  • [13] Alendronate and estrogen-progestin in the long-term prevention of bone loss: Four-year results from the early postmenopausal intervention cohort study - A randomized, controlled trial
    Ravn, P
    Bidstrup, M
    Wasnich, RD
    Davis, JW
    McClung, MR
    Balske, A
    Coupland, C
    Sahota, O
    Kaur, A
    Daley, M
    Cizza, G
    [J]. ANNALS OF INTERNAL MEDICINE, 1999, 131 (12) : 935 - +
  • [14] How can we reduce the burden of osteoporosis? - Introduction
    Woolf, AD
    Delmas, PD
    [J]. BAILLIERES CLINICAL RHEUMATOLOGY, 1997, 11 (03): : 451 - 457
12